Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(55)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 NWqwS2dbS3m2b4TvfIlkKEG|c3H5 NGfyXVcyOCCwTR?= MkjLO|IhcA>? MVnEUXNQ MULQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= MmCzNlQ6ODB6N{O=
HT-29 Mn31R5l1d3SxeHnjJGF{e2G7 NV61fopzOTBibl2= M1Hqb|czKGh? MmX3SG1UVw>? NE\sNJJRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= NHn1clczPDlyMEi3Ny=>
HT-29 MXjDfZRwfG:6aXOgRZN{[Xl? MnzlNVAhdk1? NEXJbog4OiCq MYnEUXNQ MXfQc5RmdnSrYYTld{A2NW[udX;yc5Vz[WOrbD3pcoR2[2WmIHP5eI91d3irY3n0fS=> M3q3b|I1QTByOEez
PC3 MmTYT4lv[XOnIFHzd4F6 NUTKdpBkOTByIH7N NEfRWG0yKGh? NWXiT3pITE2VTx?= MYjQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= M1XqeFIyQTd6Nkiz
PC3 NGfhWXFMcW6jc3WgRZN{[Xl? MmGyNVAxKG6P MVqxJIg> MVfEUXNQ Mni3SI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MknsNlE6Pzh4OEO=
PC3 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqyNU42KM7:TR?= Mm[3NUBp M1n6VmROW09? NYjZSI1pUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N M3G1eFIyQTd6Nkiz
HEK293 NXzvPG1iTnWwY4Tpc44hSXO|YYm= MWexNFAhdk1? M3zkblghcA>? NVznZ|dKTE2VTx?= M{W4UGlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= NYHufGM6OjF3M{mzNFE>
BT-20 NV\XdnFIU2mwYYPlJGF{e2G7 M4HJT|IxKM7:TR?= NWfESWhWTE2VTx?= NF3aV4VFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= NH24XFYzOTN3M{W1NS=>
U937 NYPTepQ2SW62aXLhZ5RmemmjbDDBd5NigQ>? NVHleGVUPTBizszN MkfvOFghcA>? NH3lcpJFVVOR M3vmTWlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= M3L2RVIyOTR{MUC2
U937 MoSxRY51cWKjY4TldolidCCDc4PhfS=> MkW0OVAh|ryP NXfTTW0yPDhiaB?= M3O3fmROW09? NIOyXGZFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| MX[yNVE1OjFyNh?=
U937 NXvmbJVzSW62aXLhZ5RmemmjbDDBd5NigQ>? M1T1TFUxKM7:TR?= M4nkclQ5KGh? M3GydGROW09? MnjXSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> NULDV5RPOjFzNEKxNFY>
MCF-7 MUTBeZRweGijZ4mgRZN{[Xl? NGGzTHE{OCCwTR?= MYi0JIg> MmflSG1UVw>? NHHYZ5lKdmS3Y3XzJIF2fG:yaHHnfS=> M3PnRVIxODJ6MUO0
U87MG NEHFPVRMcW6jc3WgRZN{[Xl? MYGxJO69VQ>? Mk\yOkBp NFz1NHBFVVOR NYDzdWlpWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= M1u4S|E6QDR6NEC0
U87MG MnzJT4lv[XOnIFHzd4F6 NETqblUyKM7:TR?= Mk\YOkBp M1G2XGROW09? MlPnVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= M2Ht[VE6QDR6NEC0
U87MG M2XwfWtqdmG|ZTDBd5NigQ>? MXmxJO69VQ>? NGexfFM3KGh? NV:wUJNJTE2VTx?= MVzEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NInwTmgyQTh2OESwOC=>
U87MG M4SxbWtqdmG|ZTDBd5NigQ>? MnixNUDPxE1? NXnLVHhjPiCq MkH5SG1UVw>? M4jKeWRw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? NHT0TG4yQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb M1PsWWF2fG:yaHHnfUBCe3OjeR?= MUSwMlIh|ryP MoLoNlQhcA>? M2W3[GROW09? M4TFR2lv\HWlZYOgZZV1d3CqYXf5 NXjyUGJXOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NY\5cnJFSXW2b4DoZYd6KEG|c3H5 MWWwMlIh|ryP M4PBTlI1KGh? NYDNfnR1TE2VTx?= NGDOUHJKdmS3Y3XzJIF2fG:yaHHnfS=> Mlu0NVg{QTF7NEm=
H4 MlfoSpVv[3Srb36gRZN{[Xl? MUCwMlIh|ryP NYDUW2tsOjRiaB?= NILBUoRFVVOR M1LMXWlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> NGflfIUyQDB{NEW4OC=>
HeLa NGrhSmZHfW6ldHnvckBCe3OjeR?= NWfNdpVOOTByIH7N M1vWUFM3KGh? M3iwOWROW09? MmPTTY5lfWOnczDGVmIhUzJyOUXQMEBVOjB7OFysJHczOTBzRjDteZRidnRvdXLpdZVqfGmwQzDpcpRmemGldHnvci=> MVuxO|U3OzN6NR?=
HeLa MXfGeY5kfGmxbjDBd5NigQ>? MoTsNVAxKG6P NFLheJQ{PiCq NHe4TWhFVVOR NHewUJNKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? M{fMV|E4PTZ|M{i1
HeLa NID0U4RHfW6ldHnvckBCe3OjeR?= MWixNFAhdk1? NGLRN3Q{PiCq M{\SWWROW09? MmfVTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u MkPPNVc2PjN|OEW=
SYF Mor2SpVv[3Srb36gRZN{[Xl? NUnKeZpMOTByIH7N NWXwOGV1OjRiaB?= NE\WUWFFVVOR NWCx[ldoUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v MnTtNVc2PjN|OEW=
SYF MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:1NVAxKG6P MWiyOEBp NXnzPYs{TE2VTx?= Mm\3TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= NF63TIUyPzV4M{O4OS=>
HEK293T M1f3SmFvfGm4aYLhcEBCe3OjeR?= NXjEbZRUOSCwTR?= NWK2WId3PCCm MXHEUXNQ MUfJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= MkHKNVc1QDV3MEG=
HEK293T NWDlS4R[SW62aY\pdoFtKEG|c3H5 M1jOZVEhdk1? NI\OW|I1KGR? M4j5XGROW09? NF3ve2lKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> NWnL[243OTd2OEW1NFE>
PBMC NIWyPYFHfW6ldHnvckBCe3OjeR?= Mme3NUBvVQ>? M3HPclE1KGR? MV3EUXNQ M{jhPHJm\HWlZYOgR2NTPSCmZX7zbZR6 M1\Ob|E4PDh3NUCx
PBMC MUfGeY5kfGmxbjDBd5NigQ>? NHXpb28yKG6P NWTYdHJ6OTRiZB?= MWDEUXNQ MYPEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> M{Kx[FE4PDh3NUCx
HEK293 cells MmnCT4lv[XOnIFHzd4F6 NXrHS413PTBibl2= MXu0OUBucW5? MonuSG1UVw>? M17YeGlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? NH\TO3QyPzN3MEm1Ny=>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NW\xOZNXTnWwY4Tpc44hSXO|YYm= MlHGNVAxKG6P MmnsOEBp M1\ZTGROW09? MmrhTY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM> M{TjSFE4OTJ6Mk[y
Human mixed lymphocyte NUnqO3pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHJXGF5PSCwTR?= MXrEUXNQ NIDOcXdKSzVyPUGuOkBvVS5? NVjMUpoyOTZzOEW4OlU>
Lewis rat lymph node cells MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P1TVUh|ryP Ml3ISG1UVw>? NYjVeol5UUN3ME2yMlYh|ryP MVOxOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice NUT4bYhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H0NlExKG6P MoPFO|IhcA>? MoHFSG1UVw>? MUTJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P NXfJfoJqOTByMkG5OFg>
MRK-nu-1 NIja[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\sbWt1UUN3ME2wMlg1PSCyTR?= NEK4cW9USU6JRWK=
OCUB-M MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTVwMkSgdG0> NX;vSWVuW0GQR1XS
SF539 NWjXbZNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7HTWM2OD1zMT62JJBO M1T1UnNCVkeHUh?=
ES4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDuUYM4UUN3ME2yNU42KHCP NIG2Z41USU6JRWK=
RL95-2 NX;HdHloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO4OocxUUN3ME2xNFcheE1? NVzrVmpOW0GQR1XS
LC-2-ad MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTMTWM2OD12MkOgdG0> MV7TRW5ITVJ?
Daudi NYGzRVFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\pTWM2OD12M{SgdG0> NX;HeIYzW0GQR1XS
NTERA-S-cl-D1 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPrTWM2OD12NEOgdG0> MmXSV2FPT0WU
OS-RC-2 M2GxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjmXGM3UUN3ME22OVIheE1? MkHmV2FPT0WU
VA-ES-BJ NWj6PWp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXYTJp[UUN3ME23NlMheE1? NVLpdHh3W0GQR1XS
GR-ST NGDmSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fUWmlEPTB;OES2JJBO NXezV5g5W0GQR1XS
SW872 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfub5BPUUN3ME24OFYheE1? MoH2V2FPT0WU
NOS-1 NXTqNmJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfvTWM2OD16N{GgdG0> NHrISlBUSU6JRWK=
MC116 NY[yfW5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn5bY1KSzVyPUm4OUBxVQ>? NXS4Z5JoW0GQR1XS
NCI-H1355 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\pTWM2OD1zLkCxJI5O MWHTRW5ITVJ?
RPMI-8226 NV76c4xXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMUmgcm0> MkS3V2FPT0WU
TE-15 NXLlXWhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qwTmlEPTB;MT6zOkBvVQ>? NUHZTWZSW0GQR1XS
Ramos-2G6-4C10 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwNE[gcm0> MUHTRW5ITVJ?
KU812 NXLYWI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fSZ2lEPTB;Mj6wNUBvVQ>? NU\6ZXVFW0GQR1XS
EW-1 M3Hv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr0[HpwUUN3ME2yMlE4KG6P NGXaVnBUSU6JRWK=
KS-1 M3fufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJwNEWgcm0> MWPTRW5ITVJ?
SK-LMS-1 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGewT4ZKSzVyPUKuOFkhdk1? NHO4dGNUSU6JRWK=
TGBC1TKB NHrCOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJwNkmgcm0> NXH5cXNJW0GQR1XS
TE-6 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjwb4ZnUUN3ME2yMlc4KG6P Mm[zV2FPT0WU
ETK-1 NGHacZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJwOEKgcm0> NHW0[2ZUSU6JRWK=
BE-13 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnuVlVKSzVyPUKuPVkhdk1? M4HROnNCVkeHUh?=
A3-KAW MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rtemlEPTB;Mj65PUBvVQ>? MYnTRW5ITVJ?
TE-10 M{jCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnQWIhKSzVyPUOuN{BvVQ>? MXPTRW5ITVJ?
DOHH-2 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTNwM{Wgcm0> MYrTRW5ITVJ?
ES6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwNEOgcm0> NHPLeHhUSU6JRWK=
OPM-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfTTWM2OD12LkG1JI5O MoPSV2FPT0WU
SH-4 NEPoVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnXboxDUUN3ME20MlM1KG6P NGjNZWVUSU6JRWK=
NB13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTRwM{[gcm0> MYfTRW5ITVJ?
HUTU-80 M2LxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4npVmlEPTB;ND60NkBvVQ>? NI\EeGxUSU6JRWK=
CCRF-CEM M1HwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTRwOUSgcm0> NFS0d45USU6JRWK=
TGBC24TKB NFT6SopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HoVWlEPTB;NT61NUBvVQ>? NYf2NJVoW0GQR1XS
697 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:zOmlEPTB;Nj6yPEBvVQ>? MonMV2FPT0WU
J-RT3-T3-5 NEPZcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXkNGc3UUN3ME22MlQ3KG6P MlTIV2FPT0WU
KALS-1 M37MT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTZwNU[gcm0> NVuxPY54W0GQR1XS
no-10 NIn3coNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqyTWM2OD15LkK5JI5O M1Xx[XNCVkeHUh?=
SK-NEP-1 Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRThwN{mgcm0> MnHnV2FPT0WU
L-540 M{TITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPDXZlSUUN3ME2xNE41OiCwTR?= MmPlV2FPT0WU
JiyoyeP-2003 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTZWWVKSzVyPUGwMlk1KG6P NULtSY95W0GQR1XS
HH NVHydoJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3lcGlLUUN3ME2xNU4{QSCwTR?= MVnTRW5ITVJ?
SR MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7ofo5KSzVyPUGxMlQ2KG6P NXnsW|lIW0GQR1XS
QIMR-WIL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFzLki1JI5O NX7sVZJ7W0GQR1XS
A4-Fuk MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjYcnhEUUN3ME2xN{4yOiCwTR?= NXfZdG1xW0GQR1XS
CESS Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3lOpBKSzVyPUGzMlE{KG6P NIKyepRUSU6JRWK=
KE-37 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF4LkC3JI5O M33JTnNCVkeHUh?=
SK-UT-1 MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnlR292UUN3ME2xOk45OSCwTR?= NGHwfmdUSU6JRWK=
SIG-M5 NW\V[Y5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDOOHU5UUN3ME2xO{4zPSCwTR?= M1nSNnNCVkeHUh?=
HT M4rIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\PemlEPTB;MUeuOkBvVQ>? Mn\0V2FPT0WU
DEL NUXlPWFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXqdW1MUUN3ME2xO{46QSCwTR?= NGD6NlFUSU6JRWK=
SK-PN-DW NY\qcZM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXobHhKSzVyPUKwMlI{KG6P NWqxU|dIW0GQR1XS
RPMI-8402 M1\r[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHJNIZKSzVyPUKxMlc4KG6P MVzTRW5ITVJ?
RPMI-6666 NWjDfnpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e3PGlEPTB;MkSuOFIhdk1? NFTObHZUSU6JRWK=
NCI-H720 MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJ3LkSxJI5O NUKxWGsyW0GQR1XS
EW-16 NIHhbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS4TlI6UUN3ME2yOk45PyCwTR?= NH22WW9USU6JRWK=
BL-70 M3zob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{noOmlEPTB;MkiuN|ghdk1? MVXTRW5ITVJ?
SF126 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX6VoJFUUN3ME2zNE4{QCCwTR?= MnTMV2FPT0WU
BC-1 NWLOOoNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj4R3ZKSzVyPUOxMlI3KG6P Mn:2V2FPT0WU
MHH-PREB-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPpVWpKSzVyPUOyMlQ1KG6P MkLFV2FPT0WU
A101D M3XrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHPUFVlUUN3ME2zNk43OiCwTR?= MkPvV2FPT0WU
NMC-G1 NHHQbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrFTWM2OD1|Mz62O{BvVQ>? NFzHVZFUSU6JRWK=
LB1047-RCC M1vic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTN2Lk[5JI5O M3zJUHNCVkeHUh?=
EM-2 M3;xOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rBdmlEPTB;M{iuOVMhdk1? Mo\jV2FPT0WU
COLO-684 MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUKxdpR6UUN3ME2zPU45KG6P M4S2SHNCVkeHUh?=
Becker MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTRzLkC1JI5O M2XCVXNCVkeHUh?=
BL-41 NWXidolCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTR|Lk[2JI5O MWXTRW5ITVJ?
MDA-MB-134-VI M4LiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHlTWM2OD12ND6wNkBvVQ>? MYjTRW5ITVJ?
L-363 NV\IeWJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTR2LkezJI5O NX;Hd244W0GQR1XS
ECC4 NIPuU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTR2Lke4JI5O Mn;rV2FPT0WU
A388 NWL1R3c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fRdGlEPTB;NESuPFIhdk1? M2D6e3NCVkeHUh?=
HEL NHfxd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTR7Lke5JI5O NYTMOoROW0GQR1XS
RKO M{jSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjKSpY2UUN3ME21NE4zQSCwTR?= NUm1UoV2W0GQR1XS
KINGS-1 M4Hm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M336U2lEPTB;NUGuOVUhdk1? M2jrXXNCVkeHUh?=
EB-3 NGC3d2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPSTlFKSzVyPUWyMlY4KG6P MYTTRW5ITVJ?
ARH-77 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPofo1KSzVyPUWyMlghdk1? Mnn5V2FPT0WU
GCIY NFvDXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTV|LkS2JI5O MkTyV2FPT0WU
NCI-H1304 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jZSGlEPTB;NUeuNlIhdk1? MonyV2FPT0WU
KARPAS-299 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTZzLkiyJI5O M3\hTXNCVkeHUh?=
IA-LM MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojSTWM2OD14OD6xN{BvVQ>? Mnr6V2FPT0WU
GI-1 MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvRVXRKSzVyPUewMlM6KG6P NE[2[G1USU6JRWK=
TE-11 M4\Rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTd5LkG3JI5O NUXoZpBzW0GQR1XS
LS-411N M13td2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;vWIZKSzVyPUe3MlU4KG6P NVLac41bW0GQR1XS
no-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTh|LkK0JI5O NEXoc3ZUSU6JRWK=
MV-4-11 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zITWlEPTB;OEOuO|Mhdk1? NGftVppUSU6JRWK=
BV-173 NE\QWHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTNWWZKSzVyPUizMlk4KG6P NYHJS3U4W0GQR1XS
CMK NVPONVZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETQboRKSzVyPUi0MlE3KG6P MnvsV2FPT0WU
LC4-1 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[3S2lEPTB;OE[uO|Ihdk1? MofKV2FPT0WU
COR-L279 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTh5LkK1JI5O M4n1[HNCVkeHUh?=
NCI-H209 M1OzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTh5LkSxJI5O NF\FOo1USU6JRWK=
Raji NV3Kd2d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPxdFA2UUN3ME24PU44OiCwTR?= MXXTRW5ITVJ?
LB996-RCC MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTl|LkSzJI5O M4nPd3NCVkeHUh?=
NCI-H526 M37NcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTl|LkW5JI5O M3zSPXNCVkeHUh?=
KGN NVnyXW1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTl4LkK5JI5O NFu3SWZUSU6JRWK=
MOLT-4 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFizWoNKSzVyPUm2Mlc6KG6P NFXNbpZUSU6JRWK=
PF-382 M3zMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULicGFNUUN3ME25Ok44QSCwTR?= NFj3N5JUSU6JRWK=
BC-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUWwVpd5UUN3ME25PU4yQCCwTR?= MVjTRW5ITVJ?
KARPAS-422 Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnNTWM2OD1zMEKuNFkhdk1? MlHCV2FPT0WU
SBC-1 M1Xpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jzN2lEPTB;MUC3Mlc2KG6P NYfmeo5qW0GQR1XS
LC-1F MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO3V5pTUUN3ME2xNFgvODVibl2= M{flcnNCVkeHUh?=
GB-1 M2jGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFyOT6wNkBvVQ>? MnXzV2FPT0WU
SNB75 NWTwcVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFzOT62PUBvVQ>? NV;GVo9pW0GQR1XS
BB65-RCC MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfVTWM2OD1zMUmuPVMhdk1? MVvTRW5ITVJ?
NCI-N87 NF7xRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF{MT65PEBvVQ>? NFfxSWJUSU6JRWK=
IST-MEL1 NFvzWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTaTWM2OD1zMkKuN|ghdk1? M37p[nNCVkeHUh?=
HOP-62 NFjreHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF{Nj64PUBvVQ>? M4ToeHNCVkeHUh?=
ACN NGjtepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvWTWM2OD1zNE[uO|Uhdk1? M1LyXXNCVkeHUh?=
DMS-114 MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF3MD62O{BvVQ>? MmLEV2FPT0WU
MLMA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF3OT64PEBvVQ>? M{HoTnNCVkeHUh?=
HT-144 M{mxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjqXG9IUUN3ME2xOlUvPDNibl2= MVXTRW5ITVJ?
C2BBe1 M3\HdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LtSGlEPTB;MU[3Mlc3KG6P MWDTRW5ITVJ?
L-428 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7tXHBKSzVyPUG3O{44KG6P NUHBZlZOW0GQR1XS
DU-4475 NH[3PYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XTPGlEPTB;MUi3MlY5KG6P NV3i[pNtW0GQR1XS
CP67-MEL NYXOXWdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTvTWM2OD1zOUmuN|ghdk1? MojJV2FPT0WU
MEG-01 NW\MUHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\pSWlEPTB;MkCxMlk3KG6P NILndYZUSU6JRWK=
IST-SL2 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO4TWM2OD1{MEiuOlMhdk1? MXLTRW5ITVJ?
ES8 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6zSm9NUUN3ME2yNlUvQTRibl2= MlTPV2FPT0WU
COLO-800 NIHRZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfTTWM2OD1{M{WuNlghdk1? M1fpN3NCVkeHUh?=
MFH-ino NUfsfmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrncVF[UUN3ME2yN|UvQDRibl2= MmPzV2FPT0WU
OVCAR-4 MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf1fY1KSzVyPUKzO{4zPCCwTR?= MV\TRW5ITVJ?
PSN1 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ2Mj63NUBvVQ>? MVjTRW5ITVJ?
EW-12 NVLuRoVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ2Mz6xJI5O MXzTRW5ITVJ?
HCC1599 NX7yN3RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLwTWM2OD1{NkGuOFchdk1? NXfvZXlmW0GQR1XS
SJSA-1 NHH5R2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW0cpdKSzVyPUK3NU41PiCwTR?= MV3TRW5ITVJ?
ST486 M1i3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\mbG9PUUN3ME2yPVYvOTRibl2= Mn3MV2FPT0WU
NOMO-1 NWL6[llIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjhXWdKSzVyPUOwNE4zOSCwTR?= M1H1e3NCVkeHUh?=
MN-60 MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PnSWlEPTB;M{C1MlMzKG6P MXfTRW5ITVJ?
HCC1187 NEXXZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTwdWxEUUN3ME2zNFcvOjVibl2= NELBcGhUSU6JRWK=
SW982 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\oXVhKSzVyPUOxOE44PSCwTR?= M3r1SnNCVkeHUh?=
LB647-SCLC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTrTWM2OD1|MkiuO|Ehdk1? MULTRW5ITVJ?
HC-1 M1PkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiyb4dKSzVyPUOzOU42KG6P NHjmTXNUSU6JRWK=
EHEB NGPWRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7MdZNKSzVyPUOzO{42OiCwTR?= MlHBV2FPT0WU
TUR MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTN4Mz65OUBvVQ>? MUnTRW5ITVJ?
LU-139 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\OPYZiUUN3ME2zO|gvODJibl2= MmLWV2FPT0WU
NB1 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnwNHpRUUN3ME2zPFQvPDVibl2= M{DIfHNCVkeHUh?=
BB30-HNC MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjse21vUUN3ME2zPFgvOzJibl2= MlfMV2FPT0WU
HAL-01 M1POZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTN6OT6yOkBvVQ>? MkDkV2FPT0WU
K5 NYPhZ2VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\UZYp4UUN3ME20NVEvOzdibl2= MkW1V2FPT0WU
MZ2-MEL Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XpU2lEPTB;NEGzMlY1KG6P MXTTRW5ITVJ?
RXF393 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\rfGdlUUN3ME20NVYvPDVibl2= NXnWUVVvW0GQR1XS
NCI-H1648 NIe3VXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTRzNz61N{BvVQ>? NWLHVIkzW0GQR1XS
TE-12 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\lNWJKSzVyPUSzOE4zPiCwTR?= MkPxV2FPT0WU
EoL-1- NVXpUmhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jkeWlEPTB;NEO3Mlk5KG6P MYXTRW5ITVJ?
JAR NELi[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTR|OD62NkBvVQ>? MmrvV2FPT0WU
DSH1 M2ixWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK1c|lKUUN3ME20OVgvQTFibl2= NV\PSWM2W0GQR1XS
NCI-H187 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTR4Mj64NUBvVQ>? NUja[283W0GQR1XS
HCE-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\F[2pKSzVyPUS3O{43PiCwTR?= NEPnNndUSU6JRWK=
8-MG-BA NVHGSHZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXHZXF6UUN3ME21PFEvPTJibl2= NXvGSpNpW0GQR1XS
KLE M2TqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXBd2lJUUN3ME21PFUvOiCwTR?= M2rPOXNCVkeHUh?=
KNS-42 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHoTWM2OD13OE[uPFEhdk1? NXflRo4zW0GQR1XS
MSTO-211H NETLe2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrMUJZKSzVyPU[wPU44PCCwTR?= MYrTRW5ITVJ?
GDM-1 M2ryVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTZzND6wPUBvVQ>? M4DnV3NCVkeHUh?=
TE-1 M4Pvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTZ2Nj6xNkBvVQ>? MkLKV2FPT0WU
BT-474 M4m2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj3TWM2OD14NEeuNFYhdk1? NUi3TFFEW0GQR1XS
KARPAS-45 M{\3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTZ2Nz62JI5O MXTTRW5ITVJ?
MOLT-16 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HLemlEPTB;NkS3Mlk{KG6P MWLTRW5ITVJ?
KURAMOCHI M3G4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vXfWlEPTB;NkW3MlUyKG6P MV\TRW5ITVJ?
K-562 NETsZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVryN29nUUN3ME22OlkvPTFibl2= NFPCRmlUSU6JRWK=
EKVX M1fSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof3TWM2OD14N{KuO|Ehdk1? MnPtV2FPT0WU
GAK NGO3WoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DKd2lEPTB;Nke1MlMhdk1? M32ySnNCVkeHUh?=
NCI-SNU-5 NF\oXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nKXGlEPTB;NkmwMlAyKG6P MVnTRW5ITVJ?
NCI-H2126 M2Tt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnPN5ZOUUN3ME23NlYvQDdibl2= MW\TRW5ITVJ?
CTV-1 M1rvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITNd2VKSzVyPUe0OE46KG6P M1rBV3NCVkeHUh?=
SW962 MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO3TWM2OD15NEiuOFQhdk1? NHrUfpZUSU6JRWK=
MONO-MAC-6 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfrfGVPUUN3ME23OVYvQTNibl2= MU\TRW5ITVJ?
NCI-H748 NHS4UWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LDfmlEPTB;N{W4Mlk6KG6P NXPjXmZSW0GQR1XS
NCI-H524 NFXhVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTd6MD63N{BvVQ>? M1TDXHNCVkeHUh?=
LS-123 NFzHUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojUTWM2OD15OUWuOlkhdk1? MUfTRW5ITVJ?
NB7 NGL3VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnDNWg2UUN3ME24NVQvOTRibl2= MX\TRW5ITVJ?
LS-1034 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnJO4RKSzVyPUiyPE46QCCwTR?= NV:0ZXFwW0GQR1XS
TE-5 M{HqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDyTWM2OD16OEOuOVYhdk1? Ml;vV2FPT0WU
A704 NWHSdZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDp[IRqUUN3ME24PVkvOTVibl2= MWPTRW5ITVJ?
TK10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTlzNj6wN{BvVQ>? NUHnW3hlW0GQR1XS
NCI-H345 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\RNWlEPTB;OUSzMlIzKG6P MUjTRW5ITVJ?
CGTH-W-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjjVpNKSzVyPUm0PE4yOyCwTR?= M3rLRXNCVkeHUh?=
NCI-H510A M{fVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\yUmJ{UUN3ME25PFUvOTJibl2= MnLBV2FPT0WU
NCI-H1963 MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;MZoFKSzVyPUGuNFMzQTJizszN MknXV2FPT0WU
SCC-3 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTvbpVKSzVyPUGuNFM1OTRizszN NGfSR4lUSU6JRWK=
EW-11 NY\pT2lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHTTWM2OD1zLkC4O|Q{KM7:TR?= MVvTRW5ITVJ?
CPC-N M3LIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjXRoZKSzVyPUGuNFg5KM7:TR?= MlHUV2FPT0WU
NCI-H1417 NXv6NWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W4UmlEPTB;MT6xNlI3KM7:TR?= MoHGV2FPT0WU
DG-75 M{fhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjYTWM2OD1zLkG2Nlg2KM7:TR?= MW\TRW5ITVJ?
HD-MY-Z NYLoeYhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnUTWM2OD1zLkG2OFE3KM7:TR?= MYDTRW5ITVJ?
ATN-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFwMk[yNFkh|ryP NV7aWGNFW0GQR1XS
KM-H2 M3yxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rXZmlEPTB;MT6yOlQxQCEQvF2= M3rxe3NCVkeHUh?=
NCI-H2081 M1vmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr4TWM2OD1zLkK2OlM4KM7:TR?= Mnz0V2FPT0WU
HL-60 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYThNFV[UUN3ME2xMlI3QTV7IN88US=> NEXMRlZUSU6JRWK=
DB MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:3VWlEPTB;MT6yO|I1OiEQvF2= NVPicZlYW0GQR1XS
NCI-H1522 NXW4N4ttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMki4PFch|ryP MknpV2FPT0WU
AM-38 NIq4flRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XvfGlEPTB;MT6zNFczKM7:TR?= NInvcmRUSU6JRWK=
NCI-H446 M{HxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwM{KxNlEh|ryP MojaV2FPT0WU
SU-DHL-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom0TWM2OD1zLkOyPFAyKM7:TR?= NYrVT2NGW0GQR1XS
NH-12 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTNTWM2OD1zLkO2N|c1KM7:TR?= MVjTRW5ITVJ?
DMS-79 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULWcnkxUUN3ME2xMlM3QDZ4IN88US=> NX;rW3pTW0GQR1XS
NCI-H716 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon2TWM2OD1zLkO4PVg3KM7:TR?= M1mwU3NCVkeHUh?=
ML-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwNEG1Nlkh|ryP NUTONXk6W0GQR1XS
NB10 NXq0UIZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwNE[2N|Ih|ryP NGjCNWNUSU6JRWK=
ONS-76 NG\xcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHITWM2OD1zLkWzOVY6KM7:TR?= M1e4XHNCVkeHUh?=
LOUCY NVHWUY1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzNTWM2OD1zLkW0OlU4KM7:TR?= NWLDZXdvW0GQR1XS
SCLC-21H NY\TZnV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnxTWM2OD1zLkW4OVgzKM7:TR?= MVnTRW5ITVJ?
TGW NYXoVHhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV30epZCUUN3ME2xMlY{QTd3IN88US=> M{ez[3NCVkeHUh?=
LXF-289 Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwN{OyOlgh|ryP NHLHfIZUSU6JRWK=
BB49-HNC M{OwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwN{O1PFYh|ryP NWLXbHVWW0GQR1XS
NCI-H747 NITRbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGGwfndKSzVyPUGuO|U{PDZizszN NHP6XYlUSU6JRWK=
LU-165 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPITWM2OD1zLki0PVg3KM7:TR?= M{PB[HNCVkeHUh?=
OMC-1 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLUTWM2OD1zLkm1NFY3KM7:TR?= MnvGV2FPT0WU
RCC10RGB NXTVXXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v3NGlEPTB;MT65OVgyPyEQvF2= MnThV2FPT0WU
SW684 M2fiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFwOU[wPVkh|ryP MXTTRW5ITVJ?
TE-8 NITpO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3jTWM2OD1{LkC1OVU6KM7:TR?= M{HwZnNCVkeHUh?=
SK-N-DZ NH3YVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH23ZnZKSzVyPUKuNVMzPzRizszN NIH6eolUSU6JRWK=
EVSA-T NWThdXRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrhfmZNUUN3ME2yMlE4OzF3IN88US=> M3:0RnNCVkeHUh?=
KASUMI-1 M3HzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;wTWM2OD1{LkG4PFE2KM7:TR?= MYHTRW5ITVJ?
NKM-1 NVu5RWJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fBZ2lEPTB;Mj6yOVQ4OiEQvF2= MXXTRW5ITVJ?
CAL-148 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\QdJY1UUN3ME2yMlM{PjF2IN88US=> NV\TPHhGW0GQR1XS
NCI-H64 M3jkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwM{SyN|Ih|ryP MlPFV2FPT0WU
KNS-81-FD Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CyVmlEPTB;Mj6zOlYzKM7:TR?= NVfISpI5W0GQR1XS
KM12 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPhSlZHUUN3ME2yMlQxQDN7IN88US=> MVvTRW5ITVJ?
SW954 M4\ERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfSdmJKSzVyPUKuOFc4PzlizszN NVu4[GtbW0GQR1XS
NCI-H1395 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJwNUK2OFUh|ryP NIjZXW5USU6JRWK=
DJM-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33Hd2lEPTB;Mj62NFY{KM7:TR?= MmPuV2FPT0WU
COLO-668 NHWxXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTiU5pCUUN3ME2yMlgzPjl3IN88US=> Mn\xV2FPT0WU
NCI-H1436 NH;lc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC4TWM2OD1{Lki1OlE2KM7:TR?= M3HIXXNCVkeHUh?=
LB2241-RCC NUfFRoJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHJUHJ{UUN3ME2yMlg3QDN7IN88US=> MX3TRW5ITVJ?
GT3TKB MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXVTWM2OD1{Lki5NFU2KM7:TR?= Mme3V2FPT0WU
COLO-824 NF3HOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zDdGlEPTB;Mj64PVc3QCEQvF2= NUjqeGR5W0GQR1XS
ES1 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTqRYVWUUN3ME2yMlg6QDd7IN88US=> NYfhdXBCW0GQR1XS
LB771-HNC NWnSbmxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nZVWlEPTB;Mj65NFk1PiEQvF2= NWD1dGhTW0GQR1XS
GI-ME-N MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTNwMEC5NFQh|ryP NIXqOIlUSU6JRWK=
NALM-6 NHrFcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLtWYRoUUN3ME2zMlAxQTN|IN88US=> MlH1V2FPT0WU
LU-134-A NVHsOphJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e4fmlEPTB;Mz6wOVQzPSEQvF2= NWi0TodiW0GQR1XS
DMS-153 M2PzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwMEW4NlQh|ryP Ml\XV2FPT0WU
MZ1-PC M4K5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n1eWlEPTB;Mz6wPVA4QCEQvF2= MknxV2FPT0WU
NCI-H1155 MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNwMUG2NUDPxE1? M{O1OHNCVkeHUh?=
CAS-1 NV;lO4dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLuTWM2OD1|LkGzO|A4KM7:TR?= Mn7PV2FPT0WU
D-502MG NX\MXZRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPjTWM2OD1|LkG0N|kh|ryP NFPaU3VUSU6JRWK=
NCI-H2141 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG2TmFPUUN3ME2zMlE4PDV{IN88US=> NUjTN3BIW0GQR1XS
NB6 NHPOb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXsd2pRUUN3ME2zMlE5OjV7IN88US=> M4f1N3NCVkeHUh?=
NCCIT NHTZN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki5TWM2OD1|LkKxPFA6KM7:TR?= MmjyV2FPT0WU
NB69 M3TodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTNwM{G4PVEh|ryP NWe0d4pvW0GQR1XS
JVM-2 MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy2Z3F[UUN3ME2zMlM3PDN|IN88US=> M1z6VHNCVkeHUh?=
K052 NW\BeZN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTCTWM2OD1|LkO3PVY5KM7:TR?= NHXUWG5USU6JRWK=
HCC2157 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XvU2lEPTB;Mz61N|IzQCEQvF2= NY\mc3hXW0GQR1XS
KMOE-2 M1jSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHGSWhRUUN3ME2zMlU1OjR{IN88US=> NX;yT404W0GQR1XS
SF268 MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHBWnRKSzVyPUOuO|E2PTRizszN NIrsUVhUSU6JRWK=
CHP-126 Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNwN{[0OVgh|ryP M3rrT3NCVkeHUh?=
CP66-MEL MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7GTWM2OD1|Lke5NFk1KM7:TR?= Mm\XV2FPT0WU
NCI-H69 NUfRUlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi2PXZWUUN3ME20MlAyQTN4IN88US=> Ml;SV2FPT0WU
A253 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTRwMEKxNFEh|ryP MUHTRW5ITVJ?
NB14 M{DEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHVOYpKSzVyPUSuNVA1PzlizszN MVfTRW5ITVJ?
NCI-H1694 NFqzWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\YVWhMUUN3ME20MlE{OTF{IN88US=> NHnCcoVUSU6JRWK=
NCI-H2196 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfYT5JpUUN3ME20MlE4OTZ7IN88US=> MWjTRW5ITVJ?
TE-9 NVXYR3I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnztTWM2OD12LkG3OVgzKM7:TR?= NVvlSG1XW0GQR1XS
D-283MED NVro[3NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLOcI9jUUN3ME20MlE5QDRizszN MULTRW5ITVJ?
OCI-AML2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxWphCUUN3ME20MlE6PDh7IN88US=> M3mxOHNCVkeHUh?=
D-263MG NYq2UIJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRwMkK5OlEh|ryP M4PVb3NCVkeHUh?=
MPP-89 M2\pO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\qXlhIUUN3ME20MlI4OzB2IN88US=> MU\TRW5ITVJ?
LAMA-84 M4PFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fZdmlEPTB;ND6zNFQzOSEQvF2= NUj4OFI6W0GQR1XS
LB373-MEL-D M4TK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDrTWM2OD12LkO2O|g6KM7:TR?= MVnTRW5ITVJ?
UACC-257 NYHteIRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTuTWM2OD12LkO5OVM1KM7:TR?= M1T2PHNCVkeHUh?=
MC-CAR M33rW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTRwNEO5PUDPxE1? MXrTRW5ITVJ?
COLO-320-HSR MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW2TWM2OD12LkS0OFI4KM7:TR?= MXvTRW5ITVJ?
P30-OHK NWryNHU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHpZpdKSzVyPUSuOlY2QDFizszN MljrV2FPT0WU
UACC-812 M1\oOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGraR3pKSzVyPUSuOlkyPjFizszN M1fCTXNCVkeHUh?=
CTB-1 M1PsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXGPYFKSzVyPUSuO|E2PTVizszN NFfodG1USU6JRWK=
ALL-PO M1vhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTRwOESwO|ch|ryP NVPudpZ5W0GQR1XS
SK-MEL-2 NG\hT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfi[W1KSzVyPUSuPFY6PTVizszN NVPTe2p4W0GQR1XS
TC-YIK M2XB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n5RmlEPTB;ND65O|k1OiEQvF2= MVHTRW5ITVJ?
NCI-H1882 M2DPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DM[2lEPTB;NT6wNlAxOSEQvF2= NVq3TXEyW0GQR1XS
MHH-CALL-2 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPZTWM2OD13LkC1NFQzKM7:TR?= NF:3[|BUSU6JRWK=
U-87-MG NYfY[pBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHxSmxKSzVyPUWuNFk1PjZizszN NIDtXVlUSU6JRWK=
NCI-H1092 M{PLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTVwMk[1OVUh|ryP MnPaV2FPT0WU
TE-441-T MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHMTWM2OD13LkK3PFIh|ryP NGnMbFlUSU6JRWK=
SK-MEL-1 NHzDZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTVwMkmwOFQh|ryP M1P6bXNCVkeHUh?=
EW-22 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nDXmlEPTB;NT6yPVQ3PiEQvF2= MmnaV2FPT0WU
MZ7-mel NYjDR3ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTVwNEC2PVEh|ryP M{fweHNCVkeHUh?=
LP-1 NGHVenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfsTWM2OD13LkSxNlkyKM7:TR?= NF22OWpUSU6JRWK=
NCI-SNU-16 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTVwNkSwO|Qh|ryP MnzrV2FPT0WU
LU-65 MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTVwN{[zO|Mh|ryP MXHTRW5ITVJ?
CW-2 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nl[2lEPTB;NT64OVk2QSEQvF2= M{W0RXNCVkeHUh?=
WSU-NHL NVTK[ZFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vWXmlEPTB;NT65OVE4PCEQvF2= NFHtWldUSU6JRWK=
IST-MES1 NHyyNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XSVmlEPTB;NT65OVQ1OyEQvF2= MYnTRW5ITVJ?
U-266 M1;0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTVwOUiyNFIh|ryP MnP1V2FPT0WU
TALL-1 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zIVmlEPTB;Nj6xOFY5QCEQvF2= MYXTRW5ITVJ?
Calu-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPCTWM2OD14LkG1N|E3KM7:TR?= NUfIbVJWW0GQR1XS
MMAC-SF M321dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTZwMUi1OVYh|ryP NVLRcpU6W0GQR1XS
NCI-H82 M3HaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT5U3FTUUN3ME22MlIxPDh7IN88US=> NV;xdYNjW0GQR1XS
RS4-11 NIW4c5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULMTFRvUUN3ME22MlI2QDl5IN88US=> MWrTRW5ITVJ?
SNU-C2B M1[yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnyb3JKSzVyPU[uOFA6PjlizszN NH;qPIRUSU6JRWK=
BOKU NV73boZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTZwNEe1PVch|ryP NGW2UmNUSU6JRWK=
C8166 NVfpfVdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHCcVZEUUN3ME22MlU2QTF{IN88US=> MknRV2FPT0WU
D-247MG M4Dld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPTdG46UUN3ME23MlA1OzR5IN88US=> M2rJWnNCVkeHUh?=
EW-18 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TLcGlEPTB;Nz6wO|I6OiEQvF2= M4DNWHNCVkeHUh?=
KG-1 M3jkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFexV2RKSzVyPUeuOlI4OzhizszN MXnTRW5ITVJ?
REH M4XKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPqbo1wUUN3ME23MlY5OTB7IN88US=> MofRV2FPT0WU
U-698-M MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTdwOESzNVUh|ryP M2XR[XNCVkeHUh?=
KP-N-RT-BM-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrFTI94UUN3ME23Mlk{ODJ7IN88US=> NWeySGU3W0GQR1XS
MS-1 NV7JZnZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTdwOU[wOFEh|ryP MUnTRW5ITVJ?
SNU-C1 Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj3TWM2OD15Lkm4NVkzKM7:TR?= MV\TRW5ITVJ?
SK-MM-2 MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e5SWlEPTB;OD6yOlA3PSEQvF2= NWDpe25HW0GQR1XS
LAN-6 NGLwV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn31TWM2OD16LkOwNFAyKM7:TR?= NI\Ibm1USU6JRWK=
NEC8 M{G4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL4dFRKSzVyPUiuN|A3QTFizszN Mnz2V2FPT0WU
NCI-H1770 M1zaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm2PFJHUUN3ME24MlM5ODB{IN88US=> NFfSNVlUSU6JRWK=
D-336MG M2L5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPxTWM2OD16LkSwNVE3KM7:TR?= M2TvOnNCVkeHUh?=
COLO-829 M3TyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rMfmlEPTB;OD60PFg4QSEQvF2= MmnrV2FPT0WU
LS-513 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLV[lVKSzVyPUiuOVk2QTlizszN NXrPbFRmW0GQR1XS
YT MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HISGlEPTB;OD62NlQzPyEQvF2= MWLTRW5ITVJ?
EW-24 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLjTWM2OD16Lke2OVQh|ryP NX3hb4M2W0GQR1XS
IST-SL1 M4XSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULZSGFPUUN3ME24Mlg3PTR|IN88US=> Mn\KV2FPT0WU
CA46 NUG4VoFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHMXYFtUUN3ME24Mlk2ODl6IN88US=> MV3TRW5ITVJ?
NCI-H1838 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDJdYxKSzVyPUiuPVg3ODJizszN MnTUV2FPT0WU
NCI-H719 NITNPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DpS2lEPTB;OT6yOVI4QSEQvF2= M3Xk[XNCVkeHUh?=
HCE-T NGDu[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYiyU3A3UUN3ME25MlMxQDVzIN88US=> NU[1Z4l{W0GQR1XS
A498 NFu5bIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi2TWM2OD17LkO2NVI1KM7:TR?= MUTTRW5ITVJ?
LB831-BLC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTlwN{[1NlEh|ryP NHvYfYNUSU6JRWK=
SKM-1 NE\4eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjTNnpCUUN3ME25Mlg2QTZ|IN88US=> MV3TRW5ITVJ?
THP-1 NX\zOHVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXqTWM2OD17Lkm2PVE5KM7:TR?= MWjTRW5ITVJ?
SHP-77 NFXYWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjhTWM2OD1zMD60NFch|ryP Mn\1V2FPT0WU
EW-3 M2rJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrh[WlKSzVyPUGwMlYzQDlizszN NHjxUG5USU6JRWK=
KY821 NI\v[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrIZ|JKSzVyPUGwMlc3OyEQvF2= MWPTRW5ITVJ?
NCI-SNU-1 M3iyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFzLkCyNVch|ryP MoPOV2FPT0WU
HCC2218 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIniT|dKSzVyPUGxMlM6QDZizszN MUPTRW5ITVJ?
IM-9 M3HKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFzLkWxNFYh|ryP NVXMTo1CW0GQR1XS
NCI-H889 NWG1fZBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX0TWM2OD1zMT61N|E{KM7:TR?= NUfjfnVYW0GQR1XS
HDLM-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjVeGlNUUN3ME2xNk41OTV7IN88US=> NWqyd4JFW0GQR1XS
LB2518-MEL NHjoPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHFeFZKSzVyPUGyMlY5OTVizszN NX7BTVdMW0GQR1XS
NCI-H23 Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nhdmlEPTB;MUOuNlQzPSEQvF2= M2jTeXNCVkeHUh?=
NB17 M4rG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W3b2lEPTB;MUOuOFU4QSEQvF2= M{XCd3NCVkeHUh?=
NCI-H322M M3nXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nTR2lEPTB;MUSuOFA3QCEQvF2= NYT1co02W0GQR1XS
SUP-T1 NFHGTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofKTWM2OD1zND60NVMh|ryP NVzD[2RJW0GQR1XS
ES3 M1;WVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknjTWM2OD1zNT6wO|A{KM7:TR?= MXLTRW5ITVJ?
ES5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S0XWlEPTB;MUWuNFc5PyEQvF2= NXPES2FqW0GQR1XS
NCI-H1650 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\2e4xKSzVyPUG1MlQ6PzlizszN MlfYV2FPT0WU
NCI-H226 M{nNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILXeo1KSzVyPUG1Mlg4PjhizszN M3vPO3NCVkeHUh?=
COR-L88 M3\M[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe4TWM2OD1zNj6zNVQh|ryP M1j4SHNCVkeHUh?=
SCC-15 NFr6PFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom0TWM2OD1zNj6zPFY6KM7:TR?= NVnVSGIxW0GQR1XS
GOTO NYraOVliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF4LkS3PVMh|ryP MV7TRW5ITVJ?
SIMA MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfvOYZTUUN3ME2xOk41QDB{IN88US=> MojhV2FPT0WU
NCI-H1299 NInCcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF5LkG1PVEh|ryP M1HtbnNCVkeHUh?=
NCI-H1581 NILtdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonFTWM2OD1zNz60NlE6KM7:TR?= NUHhSoJuW0GQR1XS
MHH-NB-11 NH\WeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnwTWM2OD1zNz65Olg{KM7:TR?= NXPL[YQ6W0GQR1XS
MFM-223 NVzZWJJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF6LkC1N|gh|ryP M4ryXXNCVkeHUh?=
ES7 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zWSGlEPTB;MUiuOVQ{OSEQvF2= Mm\WV2FPT0WU
JVM-3 M4HPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrQRXVKSzVyPUG4MlcyPyEQvF2= MoHhV2FPT0WU
RL MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rme2lEPTB;MkCuN|g5KM7:TR?= NG\Ubm5USU6JRWK=
EC-GI-10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe0fpR4UUN3ME2yNU4zODRzIN88US=> M1\IZ3NCVkeHUh?=
LNCaP-Clone-FGC M3;zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISxR2lKSzVyPUKxMlY4PjhizszN MVjTRW5ITVJ?
IMR-5 M2D5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLkTWM2OD1{MT64OFk1KM7:TR?= MlHZV2FPT0WU
KP-N-YS MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Yc2lEPTB;MkGuPFc2KM7:TR?= MXHTRW5ITVJ?
Mo-T NUGzeW1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LlPWlEPTB;MkKuNlE5PSEQvF2= NHHzVpNUSU6JRWK=
NCI-H128 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWxcGt2UUN3ME2yN{42QDV|IN88US=> NWO3Z5NpW0GQR1XS
RH-1 NXHGcm9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG0To51UUN3ME2yN{44QDZ4IN88US=> NVHaWppxW0GQR1XS
NCI-H2171 M3\r[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ2LkK0PFUh|ryP NHzNOItUSU6JRWK=
RPMI-8866 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ4Lke0NkDPxE1? Ml\tV2FPT0WU
SK-N-FI NUOwTHlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz0TWM2OD1{Nz6zPFEyKM7:TR?= MXvTRW5ITVJ?
LOXIMVI NGTRcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf6emdKSzVyPUK3MlgxPTFizszN MV\TRW5ITVJ?
P31-FUJ M{LlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXTTWM2OD1|MT61N|c1KM7:TR?= NXy0fGVuW0GQR1XS
KMS-12-PE NHnnUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;sZWlEPTB;NEmuOVMxOiEQvF2= NHL2VpJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC/0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

カスタマーフィードバック (12)


Click to enlarge
Rating
Source Nat Genet, 2014, 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell, 2011, 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res, 2012, 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy, 2015, 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep, 2015, 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol, 2015, 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res, 2011, 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta, 2013, 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis, 2013, 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2011, Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Click to enlarge
Rating
Source 2013, Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

文献中の引用 (55)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ